Mark G. Carmichael

Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/<i>neu</i>Peptide (AE37) Vaccine

Jarrod P. Holmes, Linda C. Benavides, Jeremy D. Gates et al. · Journal of Clinical Oncology · 2008 · 136 citations

Medicine, Immunology, Oncology +17

The Impact of HER2/<i>neu</i>Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

Linda C. Benavides, Jeremy D. Gates, Mark G. Carmichael et al. · Clinical Cancer Research · 2009 · 116 citations

Medicine, Immunology, Oncology +17

Results of the first phase 1 clinical trial of the HER‐2/<i>neu</i> peptide (GP2) vaccine in disease‐free breast cancer patients

Mark G. Carmichael, Linda C. Benavides, Jarrod P. Holmes et al. · Cancer · 2009 · 102 citations · Full text

Medicine, Immunology, Oncology +17

Optimal dose and schedule of an HER‐2/<i>neu</i> (E75) peptide vaccine to prevent breast cancer recurrence

Jarrod P. Holmes, Jeremy D. Gates, Linda C. Benavides et al. · Cancer · 2008 · 50 citations · Full text

Medicine, Immunology, Oncology +17

Clinical and Immunologic Responses of HLA-A3+ Breast Cancer Patients Vaccinated with the HER2/ neu -Derived Peptide Vaccine, E75, in a Phase I/II Clinical Trial

Ritesh Patil, Guy T. Clifton, Jarrod P. Holmes et al. · Journal of the American College of Surgeons · 2009 · 49 citations

Medicine, Immunology, Oncology +17